Gain Therapeutics, Inc. (GANX)

$4.15

+0.14 (+3.49%)
Rating:
Recommendation:
-
Symbol GANX
Price $4.15
Beta 0.000
Volume Avg. 0.06M
Market Cap 49.316M
Shares () -
52 Week Range 2.33-9.75
1y Target Est -
DCF Unlevered GANX DCF ->
DCF Levered GANX LDCF ->
ROE -48.13% Strong Sell
ROA -51.99% Strong Sell
Operating Margin -
Debt / Equity 18.04% Neutral
P/E -
P/B 1.83 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest GANX news


Dr. Khalid Islam
Healthcare
Biotechnology
NASDAQ Global Market

Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.